Type 2 Diabetes

In this video, David Nathan, MD, discusses the side effects of weight loss caused by type 2 diabetes medications and the risks of prescribing these medications to patients without diabetes.

Hepatic steatosis was prevalent among 52% of adults with or without type 2 diabetes and no known history of metabolic dysfunction-associated steatotic liver disease, according to findings published in Obesity.

Shortages of tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, have been resolved, the FDA announced.

The FDA has lifted a clinical hold on two trials assessing an investigational treatment for people with type 1 and type 2 diabetes, Biomea Fusion announced.

Replacing ultraprocessed foods with lesser or nonprocessed options may decrease the risk of developing type 2 diabetes, results from a prospective cohort analysis in the Lancet Regional Health Europe showed.

Adults with type 2 diabetes using metformin before or during a SARS-CoV-2 infection may have a lower risk for long COVID than those using other diabetes medications, according to findings published in Diabetes Care.

In patients with basal insulin-treated type 2 diabetes, sotagliflozin was associated with greater time in range compared with placebo at 18 weeks, researchers reported at the European Association for the Study of Diabetes Annual Meeting.

The FDA has cleared a continuous glucose monitoring system with an implantable sensor that can be worn for up to 1 year for adults aged 18 years and older with type 1 or type 2 diabetes, according to a press release.

Adults who drink caffeinated beverages such as coffee or tea may have a lower risk for developing multiple cardiometabolic diseases compared with adults with low or no intake, according to study findings.

A once-weekly GLP-1/glucagon dual agonist conferred greater decreases in HbA1c and body weight than the GLP-1 receptor agonist dulaglutide for adults with type 2 diabetes, according to a presenter.